05:22 PM EDT, 04/02/2024 (MT Newswires) -- Nanobiotix ( NBTX ) said late Tuesday it completed the dose escalation part of a phase 1 study evaluating potential first-in-class radioenhancer NBTXR3 for patients with non-small cell lung cancer.

The company said the medication targets non-small cell lung cancer that cannot be treated by surgery and has come back. It is for patients who have previously been treated with definitive radiation therapy and are amenable to re-irradiation.

The University of Texas MD Anderson Cancer Center is conducting the phase 1 study as part of a collaboration with Nanobiotix ( NBTX ).

The company said the completed dose escalation part of the study established the recommended phase 2 dose for patients with inoperable, recurrent non-small cell lung cancer. The expansion part of the study is to further evaluate safety and early signals of efficacy.

Price: 6.3, Change: +0.2, Percent Change: +3.28